Sanofi Completes Dosing in Phase 1 Trial of 'Dupixent' Utilizing Alteogen's Technology
Sanofi's 'Dupixent' (ingredient: dupilumab), which utilizes Alteogen's subcutaneous (SC) injection platform technology, has completed dosing for participants in its phase 1 clinical trial.
Exterior view of Alteogen headquarters and research center in Yuseong-gu, Daejeon. Alteogen
View original imageAccording to the clinical information site ClinicalTrials on July 23, Sanofi plans to complete its phase 1 clinical trial of Dupixent, administered in combination with Alteogen's hyaluronidase 'ALT-B4' (ingredient: verahyaluronidase alpha), by September.
This phase 1 trial, which began in June, was conducted on 40 healthy adult participants. The purpose of the trial is to evaluate the pharmacokinetics (PK), safety, and anti-drug antibodies (ADA) following the co-administration of Dupixent and ALT-B4.
Hot Picks Today
"'Homeowner Lends 600 Million Won': What Is 'Seller Financing' Emerging in Gangnam Apartment Transactions?"
- "I Thought Only Korea Was Struggling, but Japan Is Worse": Yen-Dollar Exchange Rate Hits 40-Year Low... What’s Happening to the Yen?
- [Conference Call] Hyundai Motor: "Profitability to Recover in Second Half on New Models...Guidance Maintained"
- "No Air Conditioner at Home? Come Here"...Rome Takes Extraordinary Measures Amid Record Heat Wave
- "Worked as a Hostess After Retirement"... Japan Shocked by the Current Status of Former Two-Time Olympic Gymnast
The ALT-B4 used in this trial is a recombinant human hyaluronidase enzyme developed by Alteogen, enabling the subcutaneous injection of large-volume drugs and facilitating their absorption in the body. Sanofi is utilizing Alteogen's technology to develop a new formulation of Dupixent aimed at improving dosing convenience.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
